Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.59 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.54 |
| ▸ | CDK2 | P24941 | 6/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | FBP1 | P09467 | 7/20 | 0.51 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 2/20 | 0.48 |
| ▸ | CDK4 | P11802 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CCNE2 | O96020 | 4/20 | 0.46 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
| ▸ | CCND1 | P24385 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL27883952 | 0.98 | SMN1; SMN2 (0.58) | SMN1; SMN2MAPK10CCNE1CDK2CDK5 | |
| SCHEMBL6729 | 0.82 | CCNE1 (0.59) | SMN1; SMN2MAPK10CCNE1CDK2CDK5 | |
| SCHEMBL4601358 | 0.82 | SMN1; SMN2 (0.51) | SMN1; SMN2MAPK10CCNE1CDK2CDK5 | |
| SCHEMBL31247565 | 0.81 | LMNA (0.44) | SMN1; SMN2MAPK10CCNE1CDK2CDK5 | |
| SCHEMBL4479801 | 0.81 | SMN1; SMN2 (0.56) | SMN1; SMN2MAPK10CCNE1CDK2CDK5 | |
| SCHEMBL14476229 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2MAPK10CCNE1CDK2CDK5 | |
| SCHEMBL6278411 | 0.80 | SMN1; SMN2 (0.55) | SMN1; SMN2MAPK10CCNE1CDK2CDK5 | |
| SCHEMBL9974179 | 0.80 | SMN1; SMN2 (0.55) | SMN1; SMN2MAPK10CCNE1CDK2CDK5 | |
| SCHEMBL13390860 | 0.80 | CCNE1 (0.66) | SMN1; SMN2MAPK10CCNE1CDK2CDK5 | |
| SCHEMBL17353987 | 0.80 | SMN1; SMN2 (0.72) | SMN1; SMN2MAPK10CCNE1CDK2CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4558492-A1 | 3-(6-PYRIDIN-3-YL)-2-[4-(4-METHYL-4H-1,2,4-TRIAZOL-3-YL)PIPERIDIN-1-YL]BENZONITRILE DERIVATIVES AND SIMILAR COMPOUNDS AS QPCTL AND QPCT INHIBITORS FOR THE TREATMENT OF CANCER | 858 Therapeutics, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| CN-119654315-A | 3- (6-Pyridin-3-yl) -2- [4- (4-methyl-4H-1, 2, 4-triazol-3-yl) piperidin-1-yl ] benzonitrile derivatives and similar compounds as QPCTL and QPCT inhibitors for the treatment of cancer | 858治疗公司 | 2025-03-18 | — | — | CN | disclosed |
| US-20240101544-A1 | INHIBITORS OF QPCTL AND QPCT | 858 THERAPEUTICS, INC. | 2024-03-28 | — | — | US | disclosed |
| WO-2024020517-A1 | 3-(6-PYRIDIN-3-YL)-2-[4-(4-METHYL-4H-1,2,4-TRIAZOL-3-YL)PIPERIDIN-1-YL]BENZONITRILE DERIVATIVES AND SIMILAR COMPOUNDS AS QPCTL AND QPCT INHIBITORS FOR THE TREATMENT OF CANCER | 858 THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024020517-A1 | 3-(6-PYRIDIN-3-YL)-2-[4-(4-METHYL-4H-1,2,4-TRIAZOL-3-YL)PIPERIDIN-1-YL]BENZONITRILE DERIVATIVES AND SIMILAR COMPOUNDS AS QPCTL AND QPCT INHIBITORS FOR THE TREATMENT OF CANCER | 858 THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| EP-3828184-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE AND USE THEREOF AS PI3K INHIBITOR | Medshine Discovery Inc. (CN) | 2021-06-02 | — | — | EP | disclosed |
| WO-2020038394-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE AND USE THEREOF AS PI3K INHIBITOR | 南京明德新药研发有限公司 | 2020-02-27 | — | — | WO | disclosed |
| EP-2836487-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS INC (US) | 2018-10-31 | — | — | EP | disclosed |
| US-20160207940-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2016-07-21 | — | — | US | disclosed |
| US-9255108-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-20020165259-A1 | Carbon substituted aminothiazole inhibitors of cyclin dependent kinases | RAWLINS DAVID B (US) | 2002-11-07 | — | — | US | disclosed |
| EP-1087951-A4 | CARBON SUBSTITUTED AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL MYERS SQUIBB CO (US) | 2002-08-14 | — | — | EP | disclosed |
| US-6407124-B1 | ANTICARCINOGENIC, ANTIPROLIFERATIVE, ANTIINFLAMMATORY, AND ANTIARTHRITIC AGENTS; ALZHEIMER*S DISEASE AND CARDIOVASCULAR DISORDER TREATMENT | BRISTOL-MYERS SQUIBB COMPANY | 2002-06-18 | — | — | US | disclosed |
| EP-1087951-A1 | CARBON SUBSTITUTED AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065884-A1 | CARBON SUBSTITUTED AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-12-23 | — | — | WO | disclosed |
| WO-1996030370-A2 | THIAZOLE AND THIADIAZOLE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS USEFUL IN THE TREATMENT OF THROMBOCYTOPENIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-03 | — | — | WO | disclosed |
| EP-0412404-B1 | Thiazole derivatives, processes for production thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-01-31 | — | — | EP | disclosed |
| US-5369107-A | Thiazole derivatives, processes for production thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-29 | — | — | US | disclosed |
| US-5256675-A | Antirheumatic agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-10-26 | — | — | US | disclosed |
| EP-0412404-A2 | Thiazole derivatives, processes for production thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207940-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | SMN1; SMN2 1464/4885MAPK10 256/4885CCNE1 1333/4885 |
| US-20240101544-A1 | INHIBITORS OF QPCTL AND QPCT | ACAT1, ACAT2, LCAT | SMN1; SMN2 1008/4885MAPK10 1416/4885CCNE1 2029/4885 |
| US-20020165259-A1 | Carbon substituted aminothiazole inhibitors of cyclin dependent kinases | CCNK, CDK2, CCNL2 | SMN1; SMN2 4545/4885MAPK10 800/4885CCNE1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.